Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Proc Natl Acad Sci U S A ; 113(41): 11501-11506, 2016 10 11.
Artigo em Inglês | MEDLINE | ID: mdl-27663736

RESUMO

A variable region fusion strategy was used to generate an immunosuppressive antibody based on a novel "stalk-knob" structural motif in the ultralong complementary-determining region (CDR) of a bovine antibody. The potent Kv1.3 channel inhibitory peptides Moka1-toxin and Vm24-toxin were grafted into different CDRs of the humanized antibodies BVK and Synagis (Syn) using both ß-sheet and coiled-coil linkers. Structure-activity relationship efforts led to generation of the fusion protein Syn-Vm24-CDR3L, which demonstrated excellent selectivity and potency against effector human memory T cells (subnanomolar to picomolar EC50 values). This fusion antibody also had significantly improved plasma half-life and serum stability in rodents compared with the parent Vm24 peptide. Finally, this fusion protein showed potent in vivo efficacy in the delayed type hypersensitivity in rats. These results illustrate the utility of antibody CDR fusions as a general and effective strategy to generate long-acting functional antibodies, and may lead to a selective immunosuppressive antibody for the treatment of autoimmune diseases.


Assuntos
Anticorpos Bloqueadores/farmacologia , Desenho de Fármacos , Imunossupressores/farmacologia , Canal de Potássio Kv1.3/antagonistas & inibidores , Sequência de Aminoácidos , Animais , Células CHO , Bovinos , Regiões Determinantes de Complementaridade/química , Cricetinae , Cricetulus , Células HEK293 , Humanos , Ativação Linfocitária/efeitos dos fármacos , Ratos , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/farmacologia
2.
Proc Natl Acad Sci U S A ; 103(36): 13520-5, 2006 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-16938835

RESUMO

Parkinson's disease (PD) is the most frequent neurodegenerative movement disorder. Mutations in the PINK1 gene are linked to the autosomal recessive early onset familial form of PD. The physiological function of PINK1 and pathological abnormality of PD-associated PINK1 mutants are largely unknown. We here show that inactivation of Drosophila PINK1 (dPINK1) using RNAi results in progressive loss of dopaminergic neurons and in ommatidial degeneration of the compound eye, which is rescued by expression of human PINK1 (hPINK1). Expression of human SOD1 suppresses neurodegeneration induced by dPINK1 inactivation. Moreover, treatment of dPINK1 RNAi flies with the antioxidants SOD and vitamin E significantly inhibits ommatidial degeneration. Thus, dPINK1 plays an essential role in maintaining neuronal survival by preventing neurons from undergoing oxidative stress, thereby suggesting a potential mechanism by which a reduction in PINK1 function leads to PD-associated neurodegeneration.


Assuntos
Antioxidantes/farmacologia , Proteínas de Drosophila/metabolismo , Drosophila/genética , Inativação Gênica , Neurônios/efeitos dos fármacos , Substâncias Protetoras/farmacologia , Animais , Animais Geneticamente Modificados , Antioxidantes/metabolismo , Sobrevivência Celular/efeitos dos fármacos , DNA Complementar , Proteínas de Drosophila/genética , Biblioteca Gênica , Humanos , Mutação , Neurônios/classificação , Estresse Oxidativo/efeitos dos fármacos , Doença de Parkinson/etiologia , Substâncias Protetoras/metabolismo , Proteínas Quinases , Interferência de RNA , Superóxido Dismutase/metabolismo , Superóxido Dismutase/farmacologia , Vitamina E/metabolismo , Vitamina E/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA